New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
Massachusetts’ election of a Republican senator has put health reform legislation on life support. But for the health
care industry, reform is a reality that isn’t going to die.
Struggling West Lafayette life science contract research firm will search nationally for a new permanent leader.
Analysts worry about dive in already paltry sales of new blood thinner Effient
But excluding special charges, Warsaw-based orthopedic implant maker grows profits 5 percent, easily beating expectations
of Wall
Street.
Drug distribution firm that acquired former WellPoint subsidiary plans to consolidate specialty pharmacy work at local
airport facility.
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Associated X-Ray Services relocates headquarters from South Bend to Indianapolis and also announces the company has changed
its name to AXS Imaging.
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
The management change comes as the Indianapolis company’s diabetes market share has been sliding. Roche says successor will
be named “shortly.”
John J. Greisch was most recently president of international operations at Baxter International Inc.
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
RealMed enjoys a nearly 99-percent renewal rate among its current customers and attracted 4,000 new doctors
in 2009. Employment at the company is rising after a steady decline.
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional
leaders and committees in health reform process.
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel
to push.
Congress is on the cusp of transforming health insurance—if it can pass a health reform bill that was losing popularity
late in the year.
Roche Diagnostics Corp., once the darling of the U.S. diabetes-device market, is now licking its wounds. And
it’s mulling whether to keep fighting on all fronts or to pull back.
More than half of the venture capital fund’s original investors took a pass on its $58 million successor, the newly launched
INext.
